Trial Profile
Phase 1 Single-ascending Dose-escalation Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Anti-alpha2-antiplasmin (α2AP) Monoclonal Antibody TS23 in Healthy Human Volunteers
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs TS 23 (Primary)
- Indications Thrombosis
- Focus Adverse reactions; First in man
- Sponsors Translational Sciences
- 17 Sep 2015 New trial record